Myriad myPath acquired by Castle Biosciences (NASDAQ: CSTL)
Myriad Rules Based Medicine acquired by Q2 Solutions
Myriad Genetics, Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. Myriad myPath Melanoma, LLC, Laboratory, is Myriad Genetics' laboratory that offers the myPath Melanoma test and has been used by almost 40,000 patients to guide treatment decisions and has been ordered by approximately 20% of dermatopathologists in the country.